Patent Expiry

Patent/Exclusivity Expiry: ALECENSA

Other upcoming events for NUVL

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alec

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar